Oral ibandronic acid.
Roche Holdings AG is developing an oral formulation of the bisphosphonate derivative ibandronic acid as a potential treatment for metastatic bone disease in breast cancer patients; it was filed for this indication in October 2002. Roche and its Japanese subsidiary Chugai Pharmaceutical Co Ltd, in collaboration with GlaxoSmithKline plc, have also developed the formulation for the treatment of osteoporosis.
Gennari
Luigi
L
University of Siena, Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, Policlinico Le Scotte, 53100-Siena, Italy. gennari@unisi.it
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology; D001859:Bone Neoplasms / Q000188:drug therapy*; D001862:Bone Resorption / Q000188:drug therapy*; D004164:Diphosphonates / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D015507:Drugs, Investigational / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D000077557:Ibandronic Acid
D000970:Antineoplastic Agents; D004164:Diphosphonates; D015507:Drugs, Investigational; D000077557:Ibandronic Acid